Banar Maryam, Sattari-Maraji Azin, Bayatinejad Ghazal, Ebrahimi Elahe, Jabalameli Leila, Beigverdi Reza, Emaneini Mohammad, Jabalameli Fereshteh
Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Front Med (Lausanne). 2023 May 5;10:1163439. doi: 10.3389/fmed.2023.1163439. eCollection 2023.
is a little-known environmental opportunistic bacterium that can cause broad-spectrum infections. Despite the importance of this bacterium as an emerging drug-resistant opportunistic pathogen, a comprehensive analysis of its prevalence and resistance to antibiotics has not yet been conducted.
A systematic search was performed using four electronic databases (MEDLINE via PubMed, Embase, Scopus, and Web of Science) up to October 2019. Out of 6,770 records, 179 were documented in the current meta-analysis according to our inclusion and exclusion criteria, and 95 studies were enrolled in the meta-analysis.
Present analysis revealed that the global pooled prevalence of was 5.3 % [95% CI, 4.1-6.7%], with a higher prevalence in the Western Pacific Region [10.5%; 95% CI, 5.7-18.6%] and a lower prevalence in the American regions [4.3%; 95% CI, 3.2-5.7%]. Based on our meta-analysis, the highest antibiotic resistance rate was against cefuroxime [99.1%; 95% CI, 97.3-99.7%], while the lowest resistance was correlated with minocycline [4·8%; 95% CI, 2.6-8.8%].
The results of this study indicated that the prevalence of infections has been increasing over time. A comparison of the antibiotic resistance of before and after 2010 suggested there was an increasing trend in the resistance to some antibiotics, such as tigecycline and ticarcillin-clavulanic acid. However, trimethoprim-sulfamethoxazole is still considered an effective antibiotic for treating infections.
[细菌名称]是一种鲜为人知的环境机会致病菌,可引起广谱感染。尽管这种细菌作为一种新兴的耐药机会病原体很重要,但尚未对其流行率和抗生素耐药性进行全面分析。
截至2019年10月,使用四个电子数据库(通过PubMed的MEDLINE、Embase、Scopus和Web of Science)进行了系统检索。在6770条记录中,根据我们的纳入和排除标准,有179条记录被纳入当前的荟萃分析,95项研究被纳入荟萃分析。
目前的分析显示,[细菌名称]的全球合并流行率为5.3%[95%置信区间,4.1 - 6.7%],西太平洋地区的流行率较高[10.5%;95%置信区间,5.7 - 18.6%],美洲地区的流行率较低[4.3%;95%置信区间,3.2 - 5.7%]。根据我们的荟萃分析,最高的抗生素耐药率是针对头孢呋辛[99.1%;95%置信区间,97.3 - 99.7%],而最低的耐药率与米诺环素相关[4.8%;95%置信区间,2.6 - 8.8%]。
本研究结果表明,[细菌名称]感染的流行率随时间呈上升趋势。对2010年前后[细菌名称]的抗生素耐药性进行比较表明,对某些抗生素(如替加环素和替卡西林 - 克拉维酸)的耐药性呈上升趋势。然而,复方新诺明仍被认为是治疗[细菌名称]感染的有效抗生素。